Form 4: FATE Therapeutics Officer Sells Shares

FATE Therapeutics' Chief Legal and Compliance Officer, Cindy Tahl, sold 9,037 shares of common stock to cover tax obligations related to RSU vesting.

Summary

• Cindy Tahl, Chief Legal and Compliance Officer of FATE Therapeutics Inc. (FATE), reported a sale of common stock.
• On August 4, 2025, 9,037 shares of FATE common stock were sold at a weighted average price of $1.0593 per share.
• The sale was a 'sell-to-cover' transaction, automatically executed to satisfy tax withholding obligations arising from the vesting of 25,000 Restricted Stock Units (RSUs) granted on July 29, 2024.
• The transaction was not discretionary, but rather pursuant to an irrevocable election by the reporting person.
• Following the transaction, Cindy Tahl beneficially owns 397,670 shares of FATE common stock directly.

Sentiment

Score: 5

Explanation: Neutral, as the transaction is a routine, non-discretionary 'sell-to-cover' for tax purposes, which is a common event for executives and does not reflect a change in investment sentiment.

Positives

• The transaction was a routine, non-discretionary 'sell-to-cover' event, indicating a standard process for executive compensation and tax compliance.

Negatives

• No inherent negatives are indicated, as the sale was a non-discretionary transaction for tax purposes rather than a discretionary sale by the insider.

Future Outlook

No forward-looking statements or guidance are provided.

Management Comments

• The sale was automatically executed pursuant to an irrevocable election by the Reporting Person to satisfy tax withholding obligations through 'sell-to-cover' transactions and was not made at the discretion of the Reporting Person.

Industry Context

This filing pertains to a routine insider transaction and does not provide broader industry context or trends.

Related Party Transactions

• The transaction represents a standard 'sell-to-cover' arrangement to satisfy tax obligations arising from RSU vesting, which is a common and pre-arranged transaction between a company and its executives.

Stakeholder Impact

• Minimal impact on shareholders, employees, customers, suppliers, or creditors as it is a routine, non-discretionary tax-related transaction by an insider.

Key Dates

Keywords

FATE Therapeutics, FATE, Insider Trading, Form 4, Stock Sale, RSU Vesting, Tax Withholding, Cindy Tahl, Biotechnology, Pharmaceuticals